MURINE AND HUMAN INNATE LYMPHOID CELLS AND LUNG INFLAMMATION

摘要

Described herein are methods and compositions for treatment of inflammation, such as inflammation in lung and/or airway tissue, including asthma Innate lymphoid cells (ILCs), such as type 2 ILC2s, are herein described as capable of IL-33 signaling activation, leading to airway hyperresponsiveness (AHR) and inflammation. Further described is the hereto unknown discovery that ICOS-ligand is expressed in ILC2s, that ICOS binding of ICOS to ICOS-ligand is required for its function in ILC2s, and that while IL-33 treatment induces AHR in control mice, IL-33 cannot induce AHR in mice receiving treatment via anti-ICOS-ligand antibodies. These results suggest new methods and compositions targeting ICOS and ICOS-ligand, such as dual specific antibodies that recognize ICOS and ICOS-ligand, an expression profile unique to ILC2s.